EP1560581B1 - Oromukosale formulierung und herstellungsverfahren dafür - Google Patents
Oromukosale formulierung und herstellungsverfahren dafür Download PDFInfo
- Publication number
- EP1560581B1 EP1560581B1 EP03810489A EP03810489A EP1560581B1 EP 1560581 B1 EP1560581 B1 EP 1560581B1 EP 03810489 A EP03810489 A EP 03810489A EP 03810489 A EP03810489 A EP 03810489A EP 1560581 B1 EP1560581 B1 EP 1560581B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formulation
- formulation according
- mixture
- fipamezole
- oromucosal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 61
- 238000009472 formulation Methods 0.000 title claims description 41
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- KXSUAWAUCNFBQJ-UHFFFAOYSA-N 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1h-imidazole Chemical group C1C2=CC=C(F)C=C2CC1(CC)C1=CN=CN1 KXSUAWAUCNFBQJ-UHFFFAOYSA-N 0.000 claims description 41
- 239000000796 flavoring agent Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical group OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 16
- 239000007921 spray Substances 0.000 claims description 15
- 108010011485 Aspartame Proteins 0.000 claims description 14
- 235000010357 aspartame Nutrition 0.000 claims description 14
- 239000000605 aspartame Substances 0.000 claims description 14
- 229960003438 aspartame Drugs 0.000 claims description 14
- 235000019634 flavors Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000008213 purified water Substances 0.000 claims description 10
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims description 8
- 240000001890 Ribes hudsonianum Species 0.000 claims description 8
- 235000001466 Ribes nigrum Nutrition 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 8
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- XAGTWPPXXHAZMK-UHFFFAOYSA-N 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1h-imidazole;hydrochloride Chemical compound Cl.C1C2=CC=C(F)C=C2CC1(CC)C1=CN=CN1 XAGTWPPXXHAZMK-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 7
- 229960002216 methylparaben Drugs 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000006189 buccal tablet Substances 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 230000003232 mucoadhesive effect Effects 0.000 claims description 4
- 239000006190 sub-lingual tablet Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 150000002460 imidazoles Chemical class 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940098466 sublingual tablet Drugs 0.000 claims description 2
- 229950010445 fipamezole Drugs 0.000 description 34
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 231100000041 toxicology testing Toxicity 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000002565 electrocardiography Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 0 *C1(*c2ccccc2C1)C1=CN=C*1 Chemical compound *C1(*c2ccccc2C1)C1=CN=C*1 0.000 description 1
- SRTZGTVJBSGUPX-UHFFFAOYSA-N 5-(5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole Chemical compound C1C2=CC(F)=CC=C2CC1C1=CNC=N1 SRTZGTVJBSGUPX-UHFFFAOYSA-N 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- -1 fipamezole Chemical compound 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to an oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I) wherein Y is -CH 2 - or -CO-, R 1 is halogen or hydroxy, R 2 is H or halogen and R 3 is H or lower alkyl, or an acid addition salt thereof.
- the invention also relates to a process for preparing the oromucosal formulation in question.
- the compounds of the above-mentioned formula (I) are highly selective and long-acting antagonists of ⁇ 2 -adrenoceptors. The compounds are especially valuable in the treatment of cognitive disorders.
- Compounds of formula (I) and their preparation have been described in patent publication EP 0 618 906 B1. Specific examples of such compounds are 4-(2-ethyl-5-fluoroindan-2-yl)-1 H -imidazole, i.e. fipamezole, and 4-(5-fluoroindan-2-yl)-1 H- imidazole.
- the compounds of formula (I) and their salts have good properties as such, they have disadvantages, when formulated for conventional oral administration, i.e. the normal route for administering said compounds.
- a problem is that the compounds rather quickly decompose in the gastrointestinal area or other body systems prior to accessing systemic blood flow and the therapeutic target organs. This in turn significantly lowers the effect of the compounds in question.
- One object of the present invention is to provide a formulation for administering compounds of formula (I) safely and efficiently.
- Another object of the present invention is to provide a process for preparing the formulation.
- an oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I) where Y is -CH 2 - or -CO-, R 1 is halogen or hydroxy, R 2 is H or halogen and R 3 is H or lower alkyl, or an acid addition salt thereof, together with additives conventionally used in oromucosal formulations.
- the invention concerns a process for preparing the oromucosal formulation.
- Suitable additives to be used in the formulation according to the present invention are adjuvants, expedients etc. including solvents, preserving agents, flavouring agents, fillers, gelling agents and mucoadhesive polymers.
- Preferred solvents are alcohols, especially ethanol, water and mixtures thereof.
- Preferred preserving agents are lower alkyl parahydroxybenzoates, especially methyl and propyl parahydroxybenzoate, and mixtures thereof.
- Preferred flavouring agents are aspartame, artificial flavours, such as black currant 502.009, and mixtures thereof.
- the oromucosal formulation means any type of formulation administered via oral mucosa.
- Such formulations include e.g. sprays, gels, mucoadhesive buccal tablets and pastes, sublingual tablets and like.
- the formulation is preferably in the form of a spray.
- halogen refers to F, Cl, Br and I, preferably to F and Cl and most preferably to F.
- lower alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms and most preferably 1 or 2 carbon atoms.
- an acid addition salt refers to an addition salt of any pharmaceutically acceptable acid, preferably hydrochloric acid.
- an additive conventionally used in oromucosal formulations refers to any additive known by the person skilled in the art to be applicable for oromucosal formulations.
- An especially preferred active ingredient is fipamezole (JP-1730, 4-(2-ethyl-5-fluoroindan-2yl)-1 H-imidazole hydrochloride).
- a formulation containing said preferred active ingredient is prepared according to the invention by mixing and dissolving ethanol (96%), purified water, methylparahydroxybenzoate, propylparahydroxybenzoate and aspartame at room temperature, at +15 to +25 °C.
- the volume of the mixture is adjusted with purified water, followed by filtering and the desired spray formulation is recovered.
- Fipamezole (1) and ethanol (96 %) (2) are mixed and dissolved to form a solution A.
- Purified water (6), poloxamer 407 (3), liquid flavour (4), and aspartame (5) are mixed and dissolved to form a solution B.
- Solution A and solution B are cooled down to approx. +5 °C, and mixed together to form a homogenous solution. Oromucosal gel formulation is recovered.
- Fipamezole (1), carbomer 934P (2), hydroxypropylmethylcellulose (3), flavour (4), aspartame (5), and magnesium stearate (6) are mixed to form a homogenous mixture.
- the mixture is compressed to tablets of a suitable size. Mucoadhesive buccal tablets are recovered.
- Fipamezole (1), lactose monohydrate (2), flavour (5), and aspartame (6) are mixed to form a homogenous mixture.
- the mixture is granulated with 10 % aqueous solution of povidone (3).
- Granules are formed in either high-shear or low-shear mixer. Granulated mixture is let to dry. Dry, granulated mixture is passed through a screen to obtain freely flowing granulate.
- Microcrystalline cellulose (4) and magnesium stearate (7) are mixed with the granulate.
- the final blend is compressed to tablets of a suitable size. Sublingual tablets are recovered.
- Plasma levels of fipamezole were studied in healthy male volunteers after oral administration of the drug as a solution. Blood samples for pharmcokinetic evaluation were collected for 24 hours after the drug administration. The concentration of fipamezole in plasma was measured with HPLC-MS/MS, and the pharmacokinetic parameters were calculated. The pharmacokinetics of fipamezole was evaluated with TopFit 2.0 pharmacokinetic program. The C max and t max values were read from the concentration vs. time curves, and the apparent elimination phase half-lives from the terminal part of the semilogarithmic concentration vs. time curve (see Figure 1). AUC values were calculated both to infinity and up to the last collection time with quantifiable fipamezole concentration. The results are given in Table 1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (10)
- Oromucosale Formulierung, umfassend als einen Wirkstoff ein substituiertes Imidazolderivat der Formel (I)
- Formulierung nach Anspruch 1, wobei der Wirkstoff 4-(2-Ethyl-5-fluor-indan-2-yl)-1H-imidazol oder dessen Säuresalz, vorzugsweise Hydrochlorid, ist.
- Formulierung nach Anspruch 1 oder 2, wobei die Additive ausgewählt sind aus Lösungsmitteln, Konservierungsmitteln, Geschmacksstoffen und Gemischen davon.
- Formulierung nach Anspruch 3, wobei das Lösungsmittel ausgewählt ist aus Ethanol, Wasser und einem Gemisch davon.
- Formulierung nach Anspruch 3 oder 4, wobei das Konservierungsmittel ausgewählt ist aus Methyl-para-hydroxybenzoat, Propyl-para-hydroxybenzoat und einem Gemisch davon.
- Formulierung nach einem der Ansprüche 3 bis 5, wobei der Geschmacksstoff ausgewählt ist aus Aspartam, schwarzer Johannisbeere und einem Gemisch davon.
- Formulierung nach Anspruch 1, umfassend die nachfolgenden Komponenten: (a) 4-(2-Ethyl-5-fluor-indan-2-yl)-1H-imidazol oder dessen Säuresalz, vorzugsweise Hydrochlorid, (b) Ethanol und Wasser, (c) Methyl-para-hydroxybenzoat und Propyl-para-hydroxybenzoat, und (d) Aspartam und schwarze Johannisbeere.
- Formulierung nach einem der vorstehenden Ansprüche, wobei die Formulierung in Form eines Sprays, Gels, einer mucoadhäsiven Buccaltablette oder -paste, oder einer sublingualen Tablette vorliegt.
- Formulierung nach Anspruch 8, wobei die Formulierung in Form eines Sprays vorliegt.
- Verfahren zur Herstellung einer Formulierung nach Anspruch 7, umfassend das Vermischen und Auflösen von Ethanol (96%), gereinigtem Wasser, Methyl-para-hydroxybenzoat, Propyl-para-hydroxybenzoat und Aspartam bei Raumtemperatur, bei +15 bis +25°C; gefolgt von der Zugabe und dem Auflösen von 4-(2-Ethyl-5-fluor-indan-2-yl)-1H-imidazol-hydrochlorid und künstlichem Geschmacksstoff, vorzugsweise schwarze Johannisbeere 502.009A, bei Raumtemperatur, bei +15 bis +25°C; Einstellung des Volumens des Gemisches mit gereinigtem Wasser, gefolgt von Filtration und Gewinnung der gewünschten Sprayformulierung.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20022007A FI20022007A0 (fi) | 2002-11-08 | 2002-11-08 | Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi |
| FI20022007 | 2002-11-08 | ||
| PCT/FI2003/000850 WO2004041271A1 (en) | 2002-11-08 | 2003-11-10 | Oromucosal formulation and process for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1560581A1 EP1560581A1 (de) | 2005-08-10 |
| EP1560581B1 true EP1560581B1 (de) | 2007-01-10 |
Family
ID=8564916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03810489A Expired - Lifetime EP1560581B1 (de) | 2002-11-08 | 2003-11-10 | Oromukosale formulierung und herstellungsverfahren dafür |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8653122B2 (de) |
| EP (1) | EP1560581B1 (de) |
| JP (1) | JP4739758B2 (de) |
| KR (1) | KR20050072820A (de) |
| CN (1) | CN1711083B (de) |
| AU (1) | AU2003276317B2 (de) |
| BR (1) | BR0316071A (de) |
| CA (1) | CA2505139C (de) |
| DE (1) | DE60311134T2 (de) |
| DK (1) | DK1560581T3 (de) |
| ES (1) | ES2280846T3 (de) |
| FI (1) | FI20022007A0 (de) |
| IL (1) | IL167889A (de) |
| MX (1) | MXPA05004842A (de) |
| NO (1) | NO333977B1 (de) |
| NZ (1) | NZ539690A (de) |
| PL (1) | PL211756B1 (de) |
| PT (1) | PT1560581E (de) |
| RU (1) | RU2336875C2 (de) |
| WO (1) | WO2004041271A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5202841B2 (ja) | 2003-03-27 | 2013-06-05 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 医用イメージングシステム及び関心対象をセグメント化する方法 |
| JP5577021B2 (ja) * | 2005-02-17 | 2014-08-20 | アボット・ラボラトリーズ | 動物における障害を治療および予防するための薬剤組成物の経粘膜投与 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| NO852655L (no) | 1985-06-05 | 1986-12-08 | Bio Data Corp | Fremgangsmaate ved fremstilling av koaguleringsreagens for blodplasma i mikrokonsentrert tablettform. |
| US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
| US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
| ES2097155T3 (es) | 1989-10-02 | 1997-04-01 | Cima Labs Inc | Forma de dosificacion efervescente y metodo de administracion. |
| GB2244431A (en) * | 1990-05-31 | 1991-12-04 | Farmos Oy | Treatment of age related memory impairment and other cognitive disorders |
| US5541211A (en) * | 1991-06-18 | 1996-07-30 | Orion-Yhtyma Oy | Administration of atipamezole to elicit a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic transmission |
| GB9127050D0 (en) | 1991-12-20 | 1992-02-19 | Orion Yhtymae Oy | Substituted imidazole derivatives and their preparation and use |
| AU666509B2 (en) * | 1991-12-24 | 1996-02-15 | Yamanouchi Pharmaceutical Co., Ltd. | Intrabuccally disintegrating preparation and production thereof |
| US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| PT914818E (pt) | 1996-06-14 | 2005-08-31 | Kyowa Hakko Kogyo Kk | Comprimido de desintegracao rapida por via intraoral |
| DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| FR2773489B1 (fr) * | 1998-01-15 | 2001-03-23 | Immunotech Sa | Nouvelle composition destinee a la voie oromuqueuse notamment pernasale |
| FR2781152B1 (fr) * | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation |
| JP2000095674A (ja) * | 1998-09-22 | 2000-04-04 | Sato Pharmaceutical Co Ltd | 口腔内崩壊時間短縮化錠剤の製造方法及び装置 |
| US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| JO2181B1 (en) * | 1999-04-29 | 2003-04-23 | شركة جانسين فارماسوتيكا ان. في | Procalopride solution is taken by mouth |
| GB9910505D0 (en) | 1999-05-06 | 1999-07-07 | Electrosols Ltd | A method and apparatus for manufacturing consumable tablets |
| US6284270B1 (en) * | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| FR2798289B1 (fr) * | 1999-09-15 | 2004-12-31 | Cll Pharma | Formes galeniques a delitement rapide en bouche et leur procede de preparation |
| US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
| US20040039041A1 (en) | 2000-11-14 | 2004-02-26 | Antti Haapalinna | Prevention of development of dyskinesias |
| US6982286B2 (en) * | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| ATE536869T1 (de) | 2001-10-12 | 2011-12-15 | Monosolrx Llc | Auf glucan-film basierte wirkstoffverabreichungssysteme |
-
2002
- 2002-11-08 FI FI20022007A patent/FI20022007A0/fi unknown
-
2003
- 2003-11-10 DE DE60311134T patent/DE60311134T2/de not_active Expired - Lifetime
- 2003-11-10 MX MXPA05004842A patent/MXPA05004842A/es active IP Right Grant
- 2003-11-10 AU AU2003276317A patent/AU2003276317B2/en not_active Ceased
- 2003-11-10 PL PL376772A patent/PL211756B1/pl unknown
- 2003-11-10 ES ES03810489T patent/ES2280846T3/es not_active Expired - Lifetime
- 2003-11-10 CN CN2003801028856A patent/CN1711083B/zh not_active Expired - Fee Related
- 2003-11-10 US US10/534,091 patent/US8653122B2/en not_active Expired - Fee Related
- 2003-11-10 PT PT03810489T patent/PT1560581E/pt unknown
- 2003-11-10 KR KR1020057008255A patent/KR20050072820A/ko not_active Application Discontinuation
- 2003-11-10 DK DK03810489T patent/DK1560581T3/da active
- 2003-11-10 BR BR0316071-8A patent/BR0316071A/pt active Search and Examination
- 2003-11-10 JP JP2004549237A patent/JP4739758B2/ja not_active Expired - Fee Related
- 2003-11-10 EP EP03810489A patent/EP1560581B1/de not_active Expired - Lifetime
- 2003-11-10 WO PCT/FI2003/000850 patent/WO2004041271A1/en active IP Right Grant
- 2003-11-10 RU RU2005117615/15A patent/RU2336875C2/ru not_active IP Right Cessation
- 2003-11-10 CA CA2505139A patent/CA2505139C/en not_active Expired - Fee Related
-
2005
- 2005-04-06 IL IL167889A patent/IL167889A/en not_active IP Right Cessation
- 2005-04-28 NZ NZ539690A patent/NZ539690A/en not_active IP Right Cessation
- 2005-06-07 NO NO20052752A patent/NO333977B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2505139A1 (en) | 2004-05-21 |
| EP1560581A1 (de) | 2005-08-10 |
| MXPA05004842A (es) | 2005-07-22 |
| FI20022007A0 (fi) | 2002-11-08 |
| KR20050072820A (ko) | 2005-07-12 |
| NO333977B1 (no) | 2013-11-04 |
| CA2505139C (en) | 2012-02-28 |
| PL376772A1 (pl) | 2006-01-09 |
| CN1711083A (zh) | 2005-12-21 |
| PL211756B1 (pl) | 2012-06-29 |
| JP4739758B2 (ja) | 2011-08-03 |
| NO20052752L (no) | 2005-06-07 |
| US20060052429A1 (en) | 2006-03-09 |
| DK1560581T3 (da) | 2007-05-14 |
| NZ539690A (en) | 2006-11-30 |
| CN1711083B (zh) | 2010-05-12 |
| DE60311134T2 (de) | 2007-10-31 |
| AU2003276317A1 (en) | 2004-06-07 |
| RU2336875C2 (ru) | 2008-10-27 |
| JP2006506411A (ja) | 2006-02-23 |
| US8653122B2 (en) | 2014-02-18 |
| BR0316071A (pt) | 2005-09-27 |
| AU2003276317B2 (en) | 2008-08-28 |
| DE60311134D1 (de) | 2007-02-22 |
| WO2004041271A1 (en) | 2004-05-21 |
| NO20052752D0 (no) | 2005-06-07 |
| ES2280846T3 (es) | 2007-09-16 |
| PT1560581E (pt) | 2007-03-30 |
| IL167889A (en) | 2009-07-20 |
| RU2005117615A (ru) | 2006-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1208086B1 (de) | Benzamidformulierung mit histon-deacetylase-inhibitoraktivität | |
| EP2062572A1 (de) | Pharmazeutische Zusammensetzungen | |
| EP3785698B1 (de) | Pharmazeutische edaravon-zusammensetzung | |
| EP1868581B1 (de) | Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe | |
| EP2415472A1 (de) | Feste pharmazeutische zusammensetzung mit einem amorphen körper aus solifenacin | |
| EP1092431B1 (de) | Lasofoxifen enthaltende Zusammensetzungen | |
| EP2563340A2 (de) | Wasserlösliche pharmazeutische zusammensetzung | |
| EP1560581B1 (de) | Oromukosale formulierung und herstellungsverfahren dafür | |
| DE10038364A1 (de) | Pharmazeutische, Ramipril enthaltende Brauseformulierung | |
| US5091191A (en) | Pharmaceutical composition with improved dissolution property | |
| EP1581192B1 (de) | Verbesserte formulierungen mit substituierten imidazol-derivaten | |
| EP2903593B1 (de) | Tablette mit einem verbundwerkstoff mit cyclodextrin | |
| JP2006506411A5 (de) | ||
| CA1328613C (en) | Hypotensive agent comprising 4' ethyl-2-methyl-3-piperidinopropiophenone | |
| US20040039036A1 (en) | Water-soluble liquid internal medicine | |
| EP0341774A1 (de) | Pharmazeutische Lösungen von Triamteren | |
| JPS59508B2 (ja) | ノウケツカンカクチヨウザイ ２ ３− チカン −４− フクソカンジヨウアミノスルホニルベンゼンスルホンアミド ノ セイホウ | |
| CN104739817A (zh) | 丹酚酸a在制备防治口腔疾病药物中的应用及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050506 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| RAX | Requested extension states of the european patent have changed |
Extension state: LV Payment date: 20050506 Extension state: LT Payment date: 20050506 |
|
| GRAC | Information related to communication of intention to grant a patent modified |
Free format text: ORIGINAL CODE: EPIDOSCIGR1 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20060710BHEP Ipc: A61K 31/4164 20060101AFI20060710BHEP |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: LT LV |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REF | Corresponds to: |
Ref document number: 60311134 Country of ref document: DE Date of ref document: 20070222 Kind code of ref document: P |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20070321 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20070411 |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20070401057 Country of ref document: GR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20070110 |
|
| REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E001546 Country of ref document: HU |
|
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2280846 Country of ref document: ES Kind code of ref document: T3 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 |
|
| 26N | No opposition filed |
Effective date: 20071011 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071110 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD. Free format text: OY JUVANTIA PHARMA LTD#LEMMINKAEISENKATU 5#20520 TURKU (FI) -TRANSFER TO- SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD.#HAMMERSTRASSE 49#4410 LIESTAL (CH) |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20100218 AND 20100224 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Owner name: SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD., CH Effective date: 20100318 |
|
| REG | Reference to a national code |
Ref country code: HU Ref legal event code: FH1C Free format text: FORMER REPRESENTATIVE(S): DR. MOLNAR ISTVAN, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU Ref country code: HU Ref legal event code: GB9C Owner name: SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD, CH Free format text: FORMER OWNER(S): OY JUVANTIA PHARMA LTD., FI |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: SD Effective date: 20100503 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD. Free format text: SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD.#HAMMERSTRASSE 49#4410 LIESTAL (CH) -TRANSFER TO- SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD.#HAMMERSTRASSE 49#4410 LIESTAL (CH) |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20161114 Year of fee payment: 14 Ref country code: FR Payment date: 20161116 Year of fee payment: 14 Ref country code: GB Payment date: 20161123 Year of fee payment: 14 Ref country code: DK Payment date: 20161122 Year of fee payment: 14 Ref country code: DE Payment date: 20161121 Year of fee payment: 14 Ref country code: FI Payment date: 20161121 Year of fee payment: 14 Ref country code: HU Payment date: 20161020 Year of fee payment: 14 Ref country code: NL Payment date: 20161117 Year of fee payment: 14 Ref country code: CH Payment date: 20161121 Year of fee payment: 14 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20161003 Year of fee payment: 14 Ref country code: AT Payment date: 20161121 Year of fee payment: 14 Ref country code: ES Payment date: 20161122 Year of fee payment: 14 Ref country code: BE Payment date: 20161117 Year of fee payment: 14 Ref country code: SE Payment date: 20161121 Year of fee payment: 14 Ref country code: IT Payment date: 20161122 Year of fee payment: 14 Ref country code: GR Payment date: 20161128 Year of fee payment: 14 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20161024 Year of fee payment: 14 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60311134 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20171130 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20171201 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 350970 Country of ref document: AT Kind code of ref document: T Effective date: 20171110 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20171110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180510 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171110 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180604 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171111 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171110 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180731 Ref country code: BE Ref legal event code: MM Effective date: 20171130 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180602 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171110 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171110 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171110 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20181226 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171111 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171111 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191111 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171111 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171110 |